Erschienen in:
09.10.2018 | ASO Author Reflections
ASO Author Reflections: Clinical Value of PET-CT for Gastric Cancer
verfasst von:
Michihiro Kudou, MD, Toshiyuki Kosuga, MD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2018
Einloggen, um Zugang zu erhalten
Excerpt
Currently, gastric cancer (GC) patients with pathological stage (pStage) II or III are recommended to receive postoperative adjuvant chemotherapy.
1 However, survival benefits are still limited and unsatisfactory, particularly in patients with pStage III. Thus, several clinical trials are ongoing to show the superiority of neoadjuvant chemotherapy (NAC) to postoperative chemotherapy for GC patients with clinical stage (cStage) III. The assessment of lymph node metastasis and the stage of GC has generally been performed by computed tomography (CT), and it is very challenging to predict accurately pStage III before surgery because of its low sensitivity and specificity.
2 18-fluorodeoxyglucose (FDG) positron emission tomography integrated with CT (PET-CT) has been increasingly used to predict the metastasis of several malignant diseases based on its high specificity. This study focused on the roles of preoperative PET-CT in GC and investigated whether FDG uptake in the primary tumor and/or lymph nodes contributes to the screening of patients with pStage III/IV GC before surgery.
3 …
